Pharmacopée Européenne (PE) (2009) Monographies: Caractérisation des solides cristallins et partiellement cristallins par diffraction X sur poudres, 361-366; finesse des poudres, 366; aptitude à l’écoulement des poudres, 369-372; masse volumique vrac et masse volumique après tassement, 367-369; aluminium (silicate d’) et de magnésium, 1639-1640; kaolin lourd, 2759; talc, 3601 [Mongraphs: Characterization of Crystalline and Partially Crystalline Solids by Powder X-Ray Diffraction, 361-366; Powder Fineness, 366; Flowability of Powders, 369-372; Bulk Density and Tapped Density, 367-369; Aluminum (Silicate) and Magnesium, 1639-1640; Heavy Kaolin, 2759; Talc, 3601]. 8e éd., Pharmacopée Européenne de Convention, Strasbourg. (In French)

has been cited by the following article:

• TITLE: Physico-Chemical and Mineralogical Characterizations of Tchiky Clays (Thies, Senegal) for Pharmaceutical Uses

  AUTHORS: Rokhaya Sylla Gueye, Nango Gaye, Ousmane Ka, Mamadou Baldé, Adama Diedhiou, Ngoné Diouf, Samba F. Ndoye, Idrissa Ndoye, Yoro Tine, Rokhaya Gueye, Mouhamadou B. Diop, Matar Seck, Djibril Fall, Alassane Welé

  KEYWORDS: Clays, Tchiky, Minerals, Pharmacopoeia, Antioxidant Activity

  JOURNAL NAME: Journal of Minerals and Materials Characterization and Engineering, Vol.11 No.2, March 30, 2023

  ABSTRACT: Our study focused on the valuation of Tchiky clays. This work aims to evaluate its properties to explore possible uses in pharmacy. Physico-chemical and mineralogical characterizations were carried out, as well as pharmacopoeial tests and an evaluation of the antioxidant activity. Thus, chemical analysis by X-ray fluorescence spectrometry gave silicon (55.65%), iron (15.73%), aluminum (13.53%), potassium (6.05%), titanium (3.98%), magnesium (2.10%), and calcium (0.82%). X-ray diffraction showed the presence of kaolinite, quartz and illite. This study also revealed that the sample studied was essentially a plastic clay of hard consistency, with average flowability. The evaluation of the antioxidant activity gave a percentage inhibition of 62.97% for a concentration of 7.5 g/l with an IC50 of 5.5 g/l. These results should allow use as an excipient in pharmacy, particularly in liquid, semi-liquid and pasty formulations.